Transcenta Holding 관리

관리 기준 확인 3/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Xueming Qian

최고 경영자

CN¥5.6m

총 보상

CEO 급여 비율	20.3%
CEO 임기	12.2yrs
CEO 소유권	12.8%
경영진 평균 재임 기간	2.9yrs
이사회 평균 재임 기간	3.3yrs

최근 관리 업데이트

Recent updates

Calculating The Intrinsic Value Of Transcenta Holding Limited (HKG:6628)

Dec 15

CEO 보상 분석

Xueming Qian 의 보수는 Transcenta Holding 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	-CN¥359m
Mar 31 2024	n/a	n/a	-CN¥411m
Dec 31 2023	CN¥6m	CN¥1m	-CN¥463m
Sep 30 2023	n/a	n/a	-CN¥451m
Jun 30 2023	n/a	n/a	-CN¥440m
Mar 31 2023	n/a	n/a	-CN¥424m
Dec 31 2022	CN¥6m	CN¥1m	-CN¥407m
Sep 30 2022	n/a	n/a	-CN¥666m
Jun 30 2022	n/a	n/a	-CN¥925m
Mar 31 2022	n/a	n/a	-CN¥2b
Dec 31 2021	CN¥5m	CN¥1m	-CN¥2b
Sep 30 2021	n/a	n/a	-CN¥1b
Jun 30 2021	n/a	n/a	-CN¥1b
Mar 31 2021	n/a	n/a	-CN¥364m
Dec 31 2020	CN¥51m	CN¥1m	-CN¥317m
Dec 31 2019	CN¥14m	CN¥823k	-CN¥395m

보상 대 시장: Xueming 의 총 보상 ($USD 762.33K )은 Hong Kong 시장( $USD 230.70K ).

보상과 수익: Xueming 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Xueming Qian (55 yo)

12.2yrs

테뉴어

CN¥5,562,000

보상

Dr. Xueming Qian, Ph.D. has been Chief Executive Officer and Executive Director at Transcenta Holding Limited and serves as its Chairman since June 07, 2024. He was the Founder, Chairman and Chief Executiv...

리더십 팀

이름	위치	테뉴어	보상	소유권
Xueming Qian	CEO & Executive Chairman	no data	CN¥5.56m	12.79% HK$ 34.2m
Xiaolu Weng	Executive VP & CFO	3yrs	CN¥8.32m	데이터 없음
Christopher Hwang	Executive VP of Process Development & CTO	5.8yrs	데이터 없음	데이터 없음
Wei Wang	VP of Investor Relations & Capital Markets Department and Secretary to the Board	2.8yrs	데이터 없음	데이터 없음
Yi Gu	Senior VP & Head of Research	5.8yrs	데이터 없음	데이터 없음
Charlie Qi	Senior Vice President of Global Clinical Development	1.8yrs	데이터 없음	데이터 없음
Xichen Zhang	Senior Vice President of Manufacturing & Quality	2.9yrs	데이터 없음	데이터 없음
Wen-I Chang	Senior Vice President of Oncology Franchise Strategy	2.7yrs	데이터 없음	데이터 없음
Caroline Germa	Executive VP of Global Medicine Development & Chief Medical Officer	2.3yrs	데이터 없음	데이터 없음
Kwan Wai Leung	Company Secretary	3.5yrs	데이터 없음	데이터 없음

2.9yrs

평균 재임 기간

52yo

평균 연령

경험이 풍부한 관리: 6628 의 관리팀은 경험 ( 2.9 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Xueming Qian	CEO & Executive Chairman	12.2yrs	CN¥5.56m	12.79% HK$ 34.2m
Briggs W. Morrison	Chairman of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Pasi Antero Janne	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Kumar Srinivasan	Independent Non-Executive Director	2yrs	CN¥226.00k	데이터 없음
Ling Su	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Wei Chen	Independent Non-Executive Director	1.3yrs	CN¥72.00k	데이터 없음
Susan M. Jerian	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Li Xu	Member of Scientific Advisory Board	3.8yrs	데이터 없음	0.18% HK$ 475.1k
Jiasong Tang	Independent Non-Executive Director	3.3yrs	CN¥219.00k	데이터 없음
Zhihua Zhang	Independent Non-Executive Director	3.3yrs	CN¥219.00k	데이터 없음

3.3yrs

평균 재임 기간

56yo

평균 연령

경험이 풍부한 이사회: 6628 의 이사회는 경험(평균 재직 기간 3.3 년)으로 간주됩니다.

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2024/12/21 22:06
장 마감 주가	2024/12/20 00:00
수익	2024/06/30
연간 수익	2023/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

Transcenta Holding Limited 3 애널리스트 중 2 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Bing Zhao	China Renaissance Securities
Ziyi Chen	Goldman Sachs
null null	Guoyuan Securities (HK) Ltd

Transcenta Holding 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

CEO & Executive Chairman recently bought HK$61k worth of stock

CEO & Executive Chairman recently bought HK$53k worth of stock

CEO & Executive Chairman recently bought HK$64k worth of stock

CEO & Executive Chairman recently bought HK$65k worth of stock

Transcenta Holding Limited Announces the Appointment of Dr. Li Xu as A Non-Executive Director and Member of the Audit Committee

CEO & Executive Chairman recently bought HK$67k worth of stock

Recent updates

Transcenta Holding Limited Debuts Promising Anti-Tumor Activity of Novel LIV-1 Targeting ADCs with Site-Specific Conjugated Topo I Inhibitor Payload in Tumor Models at 2024 SABCS

CEO & Executive Chairman recently bought HK$61k worth of stock

CEO & Executive Chairman recently bought HK$53k worth of stock

CEO & Executive Chairman recently bought HK$64k worth of stock

CEO & Executive Chairman recently bought HK$65k worth of stock

Transcenta Holding Limited Announces the Appointment of Dr. Li Xu as A Non-Executive Director and Member of the Audit Committee

Transcenta Holding Limited to Report First Half, 2024 Results on Aug 28, 2024

CEO & Executive Chairman recently bought HK$67k worth of stock

Transcenta Holding Limited Announces Directorate and Board Changes

Consensus EPS estimates fall by 36%

Transcenta Holding Limited Announces Updates of Phase II Data from First-Line Triple Combination Trial of Osemitamab (TST001) for G/GEJ Cancer at ASCO 2024

Transcenta Holding Limited Announces Board and Nomination Changes

New minor risk - Market cap size

Consensus revenue estimates decrease by 17%, EPS upgraded

Transcenta Holding Limited, Annual General Meeting, Jun 07, 2024

Full year 2023 earnings released: CN¥1.14 loss per share (vs CN¥0.94 loss in FY 2022)

Transcenta Holding Limited to Report Fiscal Year 2023 Results on Mar 27, 2024

Calculating The Intrinsic Value Of Transcenta Holding Limited (HKG:6628)

CEO & Executive Director recently bought HK$74k worth of stock

Transcenta Holding Limited Announces the Publication of Preclinical Results of [177Lu]Lu-TST001 Radionuclide Antibody Conjugate as Potential Novel Treatment Option for Metastatic Gastric Cancer in the European Journal of Nuclear Medicine and Molecular Imaging

FDA Grants Transcenta Clearance to Proceed with Global Phase III Trial of Osemitamab (TST001) as First-Line Treatment for Gastric/Gastroesophageal Cancer Patients

New minor risk - Shareholder dilution

First half 2023 earnings released: CN¥0.58 loss per share (vs CN¥0.47 loss in 1H 2022)

Transcenta Holding Limited Announces Management Changes, Effective August 23, 2023

Transcenta Holding Limited to Report First Half, 2023 Results on Aug 22, 2023

Transcenta Holding Limited Receives Approval from China Center for Drug Evaluation to Initiate Phase II Clinical Trial of TST002(Blosozumab)

CEO & Executive Director recently bought HK$50k worth of stock

Transcenta Holding Limited Receives Approval from China CDE and South Korea MFDS to Initiate Transtar301 Global Phase III Pivotal Trial of Osemitamab (TST001)

CEO & Executive Director recently bought HK$70k worth of stock

Transcenta Holding Limited Announces Update on Efficacy Data of Osemitamab Plus Capecitabine and Oxaliplatin

CEO & Executive Director recently bought HK$54k worth of stock

Transcenta Holding Limited Presents Updated Data of Cohort C from Phase I/IIa, Multi-Center Study of Osemitamab

CEO & Executive Director recently bought HK$70k worth of stock

Transcenta Holding Limited Announces Encouraging Phase I Clinical Data of TST002 (Blosozumab) in Chinese Patients with Reduced Bone Mineral Density

Transcenta Holding Limited to Present Two Clinical Trial Progress At Asco 2023

Transcenta Holding Limited Announces Completion of Enrollment in COHorts C and G of China Phase II Study of Osemitamab (TST001) in Combination with Capecitabine and Oxaliplatin

CEO & Executive Director recently bought HK$72k worth of stock

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Transcenta Holding Limited to Present "Trial in Progress" at ASCO-GI 2023 for TST001 (Osemitamab) Combination with Nivolumab, with or without Chemotherapy in Advanced G/GEJ Cancer

Transcenta Receives IND Clearance from NMPA for Its First-In-Class Gremlin1 Targeting Antibody TST003 for the Treatment of Solid Tumors

Transcenta Holding Limited Announces Appointment of Independent Non-Executive Director and Change in the Composition of Board Committees

High number of new and inexperienced directors

CEO & Executive Director recently bought HK$78k worth of stock

Transcenta Holding Limited Provides Update on Prevalence of Claudin18.2 and PD-L1 Expression in Chinese Gastric/Gastroesophageal Junction Adenocarcinoma

Transcenta Holding Limited Receives IND Clearance from FDA for its MASP2 Targeting Antibody TST004 for Treatment of IgA Nephropathy

CEO & Executive Director recently bought HK$72k worth of stock

Transcenta Holding Limited Receives IND Clearance from FDA for Its First-In-Class Gremlin1 Targeting Antibody TST003 for the Treatment of Solid Tumors

Transcenta Holding Limited Announces that Interim Safety and Efficacy Data of Dose Expansion Cohort from the Phase I/II Study of TST001 (Osemitamab)

Transcenta Releases Encouraging Interim Safety and Efficacy Data of the TST001 (Osemitamab) and Chemotherapy Combination Expansion Cohort for First Line Claudin18.2 Positive Gastric Cancer at ESMO Congress 2022

First half 2022 earnings released: CN¥0.47 loss per share (vs CN¥10.19 loss in 1H 2021)

Transcenta Holding Limited to Report First Half, 2022 Results on Aug 29, 2022

Transcenta Holding Limited Announces the Appointment of Caroline Germa as Executive Vice President, Global Medicine Development and Chief Medical Officer

Transcenta Holding Limited Announces Change of the Chief Medical Officer

Transcenta Holding Limited Announces Resignation of Michael Ming Shi as Executive Director

Transcenta Holding Limited Announces That It Was Selected to Present the Preclinical Data of Tst004 At the 2022 Isn Frontiers Meetings of Complement-Related Kidney Diseases

Transcenta Holding Limited Announces Demise of Albert Da Zhu, an Executive Director and a Joint Company Secretary

Transcenta Holding Limited Publishes the Results of Preclinical Studies of the Company's First-In-Class Gremlin1 Targeting Antibody in the Treatment of Castration Resistant Prostate Cancer

Less than half of directors are independent

Transcenta Holding Limited Successfully Passes the Audit of EU Qualified Person for the Manufacturing of TST001

CEO & Executive Director recently bought HK$59k worth of stock

Transcenta Holding Limited, Annual General Meeting, Jun 10, 2022

Transcenta Announces First Patient Dosed in Phase IIa Study of Claudin18.2 Monoclonal Antibody TST001 Combined with Cisplatin and Gemcitabine for the First Line Treatment of Biliary Tract Cancer

Transcenta Holding Limited to Present Two Phase I Clinical Trials of Tst001 at Upcoming ASCO GI and IGCC

CEO & Executive Director recently bought HK$864k worth of stock

Transcenta Holding Limited Announces Business Update on the First Patient Dosed in Thephase Ib Clinical Trial of Humanized Anti-Vegfr-2Monoclonal Antibody Msb0254

Transcenta Holding Limited has completed an IPO in the amount of HKD 645.28 million.

Less than half of directors are independent

CEO 보상 분석

CEO